A powerful immunity you can rely on

The NEW vaccine against Swine Erysipelas and Porcine Parvovirus infection

With

Erysipelothrix rhusiopathiae can be found on most pig farms: it causes Swine Erysipelas, a worldwide disease that has an important economic impact.1 Swine Erysipelas has different clinical presentations and is capable of affecting all stages of pig production.2

Gilt and sow vaccination is essential for controlling Swine Erysipelas.

Swine Erysipelas

Characteristic skin lesions in a pig infected with E. rhusiopathiae.

◗Reproductive losses

◗Production losses

Decreased economic

performance

◗Joint infection◗Arthritis◗Chronic lameness

◗Acute death◗Pyrexia ≥ 40-42ºC◗Abortions

◗“Diamond-skin” lesions

◗Poor growth◗Decreased carcass

value

E. rhusiopathiae is zoonotic2

Porcine Parvovirus infectionPorcine Parvovirus (PPV) has spread worldwide and is endemic in most swine herds.3

An acute outbreak of disease in a non-vaccinated herd can cause devastating reproductive losses:

◗ Infertility due to resorptions in early gestation stages.

◗ Smaller litter sizes associated with embryo loss before 35 days of gestation.

◗ Increased number of mummified foetuses.

◗ Increased number of stillbirths.

◗ Increase in low birth weight piglets.

◗ Decreased farrowing rate.

Maternal reproductive failure is the major and only well-established clinical sign of PPV infection.3

Day 0 Day 6 Day 12 Day 114Day 70Day 35

Embryo FoEtuS

Conception Hatching Placentation Ossification begins FarrowingImmunological competence

Conceptus protected

Death and resorption of embryos

Foetal death and mummification

Immune response usually leads to survival

Gestation

Foetal development

Result of PPV infection

Consequences of PPV infection according to gestation time (adapted from Diseases of Swine, 10th edition)

A mix of normal pigs and mummified foetuses that died at different stages in the same litter is a strong indication of PPV infection.3

Exceptional efficacy against Swine Erysipelas thanks to two main components:◗ A highly immunogenic antigen. Its quality could be related to the

presence of the cell surface spa A protein of E. rhusiopathiae:

◗ Responsible for inducing the production of highly protective antibodies.2

◗ Considered to be the major immunizing antigen of E. rhusiopathiae.2

◗ Hipramune® Gd, a powerful adjuvant that enhances the duration of immunity against E. rhusiopathiae4: 6 months after primary vaccination.

Effectively protects sows and gilts against Porcine Parvovirus and also their progenie against transplacental infection.

The immunity conferred by Eryseng® Parvo covers the entire gestation period5,6:

◗ Females reach high PPV specific HI antibody titres.

◗ Foetuses protected against PPV infection.

◗ reduced reproductive losses:

◗ Infertility.

◗ % abnormal foetuses.

◗ Improved litter size: more total piglets born and total piglets born alive.

Highly-protective and long-lasting immunity for the breeding herd.

enhances animals’ antigen presentation process:

◗ An increase in the number of APCs and the amount of antigen on their surface is one of the keys in the ability of adjuvants to increase the effectiveness of vaccines.9

Stimulates the production and maturation of antigen presenting cells (APCs) such as dendritic cells and macrophages.7

Activates mixed cellular and humoral immune responses.7

Improves antibody production.7

Promotes antigen particulation increasing its availability.8

HIPrAmuNE®Gd is a state-of-the-art aqueous adjuvant developed by HIPrA based on GINSENG saponins with known immunological properties.

protects gilts and sows against clinical signs of Swine Erysipelas

A study was performed to compare the humoral immune responses elicited in naïve pigs against E. rhusiopathiae by three different inactivated bivalent Porcine virus (PPV) and E. rhusiopathiae vaccines.10,11 ◗ Vaccine A was ERySEng® PARVO.

◗Vaccine B was a commercially available vaccine adjuvanted with aluminium hydroxide.

◗Vaccine C was a commercially available vaccine adjuvanted with dl-α-tocopherol acetate.

1. Humoral immune response10

The humoral immune response against E. rhusiopathiae in the group of animals vaccinated with is faster,

higher and lasts longer.

results

Day 0 Day 21 Day 93

Vaccination revaccination Challenge E. rhusiopathiae: serotypes 1 and 2

is an ally in the duration of immunity against Erysipelothrix rhusiopathiaeAn immunological study was conducted to investigate the action of Hipramune®gd on the length of seroconversion against E. rhusiopathiae.4

◗ gilts were vaccinated twice intramuscularly with a 2 ml dose three weeks apart against E. rhusiopathiae with one of the following formulations: aluminium hydroxide (group A), Hipramune®gd (group B) and PBS as a negative control (group C).

* Vaccines from groups A and B contained the same concentration of E. rhusiopathiae antigen with different adjuvants.

140

120

80

100

-20

60

40

20

0

60 80 9341210

BEryseng® Parvo C Placebo

IrP

C

mean antibody levels against E. rhusioapthiae

a, b, c Different superscripts indicate statistically significant differences within the same day (Anova 1F; p<0.05).

STUDY DAY

a

a

a

aab

b

bb

b

bb

b

cc c

bc

b,c

a,b

PBS

Aluminium hydroxide Hipramune® Gd

protects gilts and sows against clinical signs of Swine Erysipelas

B C Placebo

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

Healthy Affected

B C Placebo

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

Healthy Affected

2. Body temperature after challenge11

maintains physiological

temperatures after infection.

3. Skin lesions after challenge11

is effective in reducing typical skin lesions produced after the E. rhusiopathiae infection.

Serotype 1 strain: affected animals (%) Serotype 2 strain: affected animals (%)

is an ally in the duration of immunity against Erysipelothrix rhusiopathiae

The humoral immune response against E. rhusiopathiae in the group of animals vaccinated with vaccine

containing is faster and longer.

Average body temperature (ºC) post-challenge

* Statistically significant differences within the same day (Anova 1F; p<0.05).

* Statistically significant differences with the placebo group (Anova 1F; p<0.05).

* Statistically significant differences with the same day (Anova 1F; p<0.05).

40.50

40.00

39.50

39.00

38.50

93 94 95 96 97 98 99 10038.00

STUDY DAY

Tem

pera

ture

(ºC

)

PlaceboCEryseng® Parvo B

*

* * *

* *

*

*

140

100

120

60

80

40

20

-20

00 21 60 80 9341

Group A Group B Group CSTUDY DAY

IRP

C

mean antibody levels against E. rhusioapthiae

Suspension for injection for pigs. Composition: Each dose of 2 ml contains: Active substances: Inactivated porcine parvovirus, strain nADL-2, RP > 1.15 *. Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ELISA > 3.34 IE50%** .* RP – relative potency (ELISA).

**IE50% – Inhibition ELISA 50%. Adjuvants: Aluminium hydroxide, DEAE-Dextran, ginseng. Indications: For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus. For the active immunisation of male and female pigs to reduce clinical signs of swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2. Onset of immunity: Porcine parvovirus: from the beginning of the gestation period. E. rhusiopathiae: three weeks after completion of the basic vaccination scheme. Duration of immunity: Porcine parvovirus: vaccination provides foetal protection for the duration of gestation. E. rhusiopathiae: vaccination protects against swine erysipelas until the time of the recommended revaccination (approximately six months after the basic vaccination scheme). Administration route: Intramuscular use. Dosage: Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule: Basic vaccination: Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3–4 weeks. The second injection should be administered 3–4 weeks before mating. Revaccination: A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months). Side effects & Contraindications: Very common adverse reactions: Mild to moderate inflammation at the injection site that typically resolves within four days but in some cases may persist for up to 12 days post-vaccination. Common adverse reactions: A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours. Do not use in cases of hypersensitivity to the active substance, to the adjuvants or to any of the excipients. Withdrawal period: Zero days. Special Precautions: none special warnings for each target species. Can be used during pregnancy and lactation. Vaccinate only healthy animals. In case of adverse reactions following accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. no information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. overdose: no adverse reactions other than those mentioned in section Side Effects & Contraindications were observed after the administration of a 2-fold vaccine dose. Do not mix with any other veterinary medicinal product. Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: use immediately. Special storage precautions: Store and transport refrigerated (2 - 8 ºC). Do not freeze. Protect from light. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. Keep out of the reach and sight of children. Packaging: Vials of 10, 25 and 50 doses. marketing Authorisation Holder: LABORATORIOS HIPRA, S.A. Avda. la Selva, 135. 17170 Amer (girona) Spain. Tel. (972) 430660 – Fax (972) 430661. marketing Authorization number: EU/2/14/167/001-007. Under veterinary prescription. Use medicines responsibly.

with

basic vaccination. Sows and gilts which have not been previously vaccinated revaccination.

6 - 8 weeks before AI 3-4 weeks before AI ArtIFICIAl INSEmINAtIoN

1st dose 2nd dose

2-3 weeks before AI

1st dose

ArtIFICIAl INSEmINAtIoN

A NEW vaccine for the breeding herd

laboratorios Hipra, S.A.Avda. la Selva, 13517170 Amer (girona)Spain

Tel. (34) 972 43 06 60Fax (34) 972 43 06 61hipra@hipra.comwww.hipra.com

References:

1. Muirhead MR et al. 2013. Managing pig health, 2nd ed. 2. Opriessnig T et al. 2012. Diseases of swine, 10th ed: 750-759. 3. Truyen U et al. 2012. Diseases of swine, 10th ed: 447-455. 4. Camprodon A et al. Hipramune®-gd: An ally in the duration of immunity against Erysipelothrix rhusiopathiae. IPVS proceedings vol II 2014; P634: 614. 5. Camprodon A et al. Duration of the protective immunity against Porcine Parvocirus infection after vaccination of sows using a new bivalent Parvovirus

and Erysipelas vaccine. ESPHM proceedings 2014; P229; 251. 6. Camprodon A et al. Efficacy against Porcine Parvovirus infection after vaccination of gilts using Eryseng® Parvo. IPVS proceedings vol II 2014; P636; 616. 7. Kang S, Min H. ginseng, the “Immunity Boost”: The effects of Panax ginseng on immune system. J Ginseng Res 2012; 36: 654-368. 8. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 2003; 17: 273-281. 9. Chase C. Swine immunology: What does it take to make the immune response take? AASV 2012: 411-416.10. Camprodon A et al. Evaluation of the Erysipelothrix rhusiopathiae antigenic component in bivalent Porcine Parvovirus and E. rhusiopathiae vaccines

by humoral immune responses in pigs. ESPHM proceedings 2014; P223: 248.11. Camprodon A et al. Evaluation of an Erysipelothrix rhusiopathiae experimental infection in pigs vaccinated with bivalent Porcine Parvovirus

and E. rhusiopathiae vaccines. ESPHM proceedings 2014; P222: 247.

Highly-protective and long-lasting immunity

reduction of Swine Erysipelas clinical signs

Effective protection against Porcine Parvovirus infection